Outbreak of carbapenem-resistant Providencia stuartii in an intensive care unit

Infection Control and Hospital Epidemiology

Volumn 33, Issue 6, 2012, Pages 627-630

  Zavascki, Alexandre P ^a   Carvalhaes, Cecília G ^b   da Silva, Geórgia L ^c   Tavares Soares, Sílvia Pedroso ^c   de Alcantara, Luciana R ^c   Elias, Laura S ^c   Sandri, Ana M ^c   Gales, Ana C ^b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CEFEPIME; CEFTRIAXONE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PROVIDENCIA STUARTII; PROVIDENCIA STUARTII INFECTION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BIOLOGICAL MARKERS; BRAZIL; CARBAPENEMS; CROSS INFECTION; DISEASE OUTBREAKS; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INFECTION CONTROL; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROVIDENCIA;

EID: 84860669782     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/665730     Document Type: Article

References (12)

1. Lee HW, Kang HY, Shin KS, Kim J. Multidrug-resistant Providencia isolates carrying blaPER-1, blaVIM-2, and armA. J Microbiol 2007;45:272-274.
2. Miriagou V, Tzouvelekis LS, Flevari K, Tsakiri M, Douzinas EE. Providencia stuartii with VIM-1 metallo-β-lactamase. J Antimicrob Chemother 2007;60:183-184.
3. Shiroto K, Ishii Y, Kimura S, et al. Metallo-β-lactamase IMP-1 in Providencia rettgeri from two different hospitals in Japan. J Med Microbiol 2005;54:1065-1070.
4. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-332.
5. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Thomson KS. Extended-spectrum-β-lactamase, AmpC, and carbapenemase issues. J Clin Microbiol 2010;48:1019-1025.
7. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-2239.
8. Poirel L, Naas T, Guibert M, Chaibi EB, Labia R, Nordmann P. Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum β-lactamase encoded by an Escherichia coli integron gene. Antimicrob Agents Chemother 1999;43: 573-581.
9. Picão RC, Poirel L, Gales AC, Nordmann P. Diversity of βlactamases produced by ceftazidime-resistant Pseudomonas aeru ginosa causing bloodstream infections in Brazil. Antimicrob Agents Chemother 2009;53:3908-3913.
10. Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002;40:2153-2162.
11. Hernandez-Allés S, Alberti{dotless}́ S, Alvarez D, et al. Porin expression in clinical isolates of Klebsiella pneumoniae. Microbiology 1999; 145:673-679.
12. Tran QT, Mahendran KR, Hajjar E, et al. Implication of porins in β-lactam resistance of Providencia stuartii. J Biol Chem 2010; 285:32273-32281.